Literature DB >> 24165965

Tumor gangliosides accelerate murine tumor angiogenesis.

Yihui Liu1, Assefa Wondimu, Su Yan, Daniel Bobb, Stephan Ladisch.   

Abstract

Tumor cells shed gangliosides and populate their microenvironment with these biologically active membrane glycosphingolipids. In vitro, ganglioside enrichment amplifies receptor tyrosine kinase signaling and activation of vascular endothelial cells. However, a long-standing question is whether in the actual microenvironment of a neoplasm, in vivo, tumor cell ganglioside shedding stimulates angiogenesis. Here we tested the hypothesis that tumor gangliosides have a critical proangiogenic role in vivo using novel murine tumor cells, GM3synthase/GM2synthase double knockout (DKO) cells, genetically completely incapable of ganglioside synthesis and impaired in tumor growth versus wild-type (WT) ganglioside-rich cells. We studied angiogenesis during tumor formation by these ganglioside-depleted cells, quantifying vessel formation, angiogenic factor production/release, and consequences of reconstitution with purified WT gangliosides. DKO cells formed virtually avascular tumors, much smaller than ganglioside-rich WT tumors and displaying a striking paucity of blood vessels, despite levels of VEGF and other angiogenic factors that were similar to those of WT cells. Transient enrichment of the ganglioside milieu of the DKO cell inoculum by adding purified WT gangliosides partially restored angiogenesis and tumor growth. We conclude that tumor gangliosides trigger robust angiogenesis important for tumor growth. Our findings suggest strategies to eliminate their synthesis and shedding by tumor cells should be pursued.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24165965      PMCID: PMC4004731          DOI: 10.1007/s10456-013-9403-4

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  48 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Shed tumor gangliosides and progression of human neuroblastoma.

Authors:  L Valentino; T Moss; E Olson; H J Wang; R Elashoff; S Ladisch
Journal:  Blood       Date:  1990-04-01       Impact factor: 22.113

3.  Enhancement of epidermal growth factor signaling and activation of SRC kinase by gangliosides.

Authors:  R Li; Y Liu; S Ladisch
Journal:  J Biol Chem       Date:  2001-09-04       Impact factor: 5.157

Review 4.  Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains.

Authors:  Adriane Regina Todeschini; Sen-itiroh Hakomori
Journal:  Biochim Biophys Acta       Date:  2007-10-22

5.  Membrane ganglioside enrichment lowers the threshold for vascular endothelial cell angiogenic signaling.

Authors:  Yihui Liu; James McCarthy; Stephan Ladisch
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

6.  Shedding of GD2 ganglioside in patients with retinoblastoma.

Authors:  J Portoukalian; M J David; P Gain; M Richard
Journal:  Int J Cancer       Date:  1993-04-01       Impact factor: 7.396

Review 7.  Remodeling of the microenvironment by aggressive melanoma tumor cells.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Dawn A Kirschmann; Vito Quaranta; Richard E B Seftor
Journal:  Ann N Y Acad Sci       Date:  2003-05       Impact factor: 5.691

8.  Exogenous ganglioside GD1a enhances epidermal growth factor receptor binding and dimerization.

Authors:  Yihui Liu; Ruixiang Li; Stephan Ladisch
Journal:  J Biol Chem       Date:  2004-06-23       Impact factor: 5.157

9.  Gangliosides promote the angiogenic response.

Authors:  M Ziche; G Alessandri; P M Gullino
Journal:  Lab Invest       Date:  1989-12       Impact factor: 5.662

Review 10.  Vascular endothelial growth factor (VEGF) in autoimmune diseases.

Authors:  Jozélio Freire Carvalho; Miri Blank; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2007-03-06       Impact factor: 8.542

View more
  16 in total

1.  Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.

Authors:  G M Piperno; A López-Requena; A Predonzani; D Dorvignit; M Labrada; L Zentilin; O R Burrone; M Cesco-Gaspere
Journal:  Gene Ther       Date:  2015-07-16       Impact factor: 5.250

2.  Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells.

Authors:  Assefa Wondimu; Yihui Liu; Yan Su; Daniel Bobb; Jennifer S Y Ma; Lina Chakrabarti; Saša Radoja; Stephan Ladisch
Journal:  Cancer Res       Date:  2014-08-12       Impact factor: 12.701

Review 3.  Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.

Authors:  Nora Berois; Eduardo Osinaga
Journal:  Front Oncol       Date:  2014-05-23       Impact factor: 6.244

4.  Twist promotes angiogenesis in pancreatic cancer by targeting miR-497/VEGFA axis.

Authors:  An Liu; Chenggang Huang; Xuehong Cai; Jia Xu; Dinghua Yang
Journal:  Oncotarget       Date:  2016-05-03

5.  The function of cancer-shed gangliosides in macrophage phenotype: involvement with angiogenesis.

Authors:  Tae-Wook Chung; Hee-Jung Choi; Mi-Ju Park; Hee-Jin Choi; Syng-Ook Lee; Keuk-Jun Kim; Cheorl-Ho Kim; Changwan Hong; Kyun-Ha Kim; Myungsoo Joo; Ki-Tae Ha
Journal:  Oncotarget       Date:  2017-01-17

Review 6.  Targets and Antibody Formats for Immunotherapy of Neuroblastoma.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  J Clin Oncol       Date:  2020-03-13       Impact factor: 44.544

7.  Subacute Sensorimotor Neuropathy Accompanied by Anti-ganglioside GM1 Antibody in a Patient with Lung Cancer.

Authors:  Nobuhiro Kanaji; Kodai Kume; Hitoshi Mizoguchi; Takuya Inoue; Naoki Watanabe; Noriko Nishiyama; Norimitsu Kadowaki; Tomoya Ishii
Journal:  Intern Med       Date:  2018-07-06       Impact factor: 1.271

Review 8.  Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents.

Authors:  Jose Luis Daniotti; Ricardo D Lardone; Aldo A Vilcaes
Journal:  Front Oncol       Date:  2016-01-07       Impact factor: 6.244

9.  Generation and characterization of a IgG monoclonal antibody specific for GM3 (NeuGc) ganglioside by immunizing β3Gn-T5 knockout mice.

Authors:  Dongwei He; Xiaoyan Fan; Boyi Liu; Yiqing Tian; Xiangmei Zhang; Lin Kang; Yan Tai; Shuzhen Liu; Qian Wang; Qingxia Li; Jianhui Cai
Journal:  Sci Rep       Date:  2018-02-07       Impact factor: 4.379

Review 10.  Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.

Authors:  Bassel Nazha; Cengiz Inal; Taofeek K Owonikoko
Journal:  Front Oncol       Date:  2020-07-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.